New combo therapy targets hard-to-treat colorectal cancer in early trial
NCT ID NCT07229872
First seen Nov 17, 2025 · Last updated May 06, 2026 · Updated 28 times
Summary
This early-phase study tests a combination of two drugs—aipalirovorelizumab (QL1706) and fruquintinib—in 18 adults with a specific type of advanced colorectal cancer (pMMR/MSS) that has not responded to at least two prior treatments. The goal is to see if the combination can shrink tumors and how well patients tolerate it. Participants receive the drugs intravenously and orally in 3-week cycles until the cancer worsens or side effects become too severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.